| Research and development | $63.6M+107.8% | $30.6M |
| General and administrative | $18.8M+102.4% | $9.3M |
| Total operating expenses | $82.4M+106.5% | $39.9M |
| Loss from operations | -$82.4M-106.5% | -$39.9M |
| Interest income | $14.6M+1009.7% | $1.3M |
| Change in fair value of Series B preferred stock tranche rights liability | $0+100.0% | -$13.4M |
| Total other income (expense) | $14.6M+220.6% | -$12.1M |
| Net loss before income taxes | -$67.8M-30.5% | -$52.0M |
| Income tax expense | -$187K-3640.0% | -$5K |
| Net loss | -$68.0M-30.8% | -$52.0M |
| Net Loss per share, basic (in usd per share) | -$4050.00+95.5% | -$89610.00 |
| Net Loss per share, diluted (in usd per share) | -$4050.00+95.5% | -$89610.00 |
| Weighted-average number common shares outstanding, basic (in shares) | 16.81T+2797.0% | 580.11B |
| Weighted-average number common shares outstanding, diluted (in shares) | 16.81T+2797.0% | 580.11B |
| Related Party |
| Nonrelated Party |
